Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development announced today that Selexis and Symphogen A/S have entered into a commercial license agreement and signed the continuation of their R&D license agreement. Symphogen has licensed the rights to the Selexis SUREtechnology Platformâ„¢ and SURE CHO-M Cell Lineâ„¢ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment of various cancers and infectious diseases. Symphogen has developed unique technologies for…